Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

Aripiprazole: a drug with a novel mechanism of action and possible efficacy for alcohol dependence.

Vergne DE, Anton RF.

CNS Neurol Disord Drug Targets. 2010 Mar;9(1):50-4. Review.

PMID:
20201815
2.

[Clinical impact of aripiprazole in patients suffering from schizophrenia].

Levoyer D, Drapier D, Fadier-Salicé G, Millet B.

Encephale. 2007 May-Jun;33(3 Pt 1):332-8. French.

PMID:
17675931
3.

Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study.

Mamo D, Graff A, Mizrahi R, Shammi CM, Romeyer F, Kapur S.

Am J Psychiatry. 2007 Sep;164(9):1411-7.

PMID:
17728427
4.

Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology.

Davies MA, Sheffler DJ, Roth BL.

CNS Drug Rev. 2004 Winter;10(4):317-36. Review.

5.

Aripiprazole, alcohol and substance abuse: a review.

Brunetti M, Di Tizio L, Dezi S, Pozzi G, Grandinetti P, Martinotti G.

Eur Rev Med Pharmacol Sci. 2012 Oct;16(10):1346-54. Review.

6.

Aripiprazole effects on alcohol consumption and subjective reports in a clinical laboratory paradigm--possible influence of self-control.

Voronin K, Randall P, Myrick H, Anton R.

Alcohol Clin Exp Res. 2008 Nov;32(11):1954-61. doi: 10.1111/j.1530-0277.2008.00783.x. Epub 2008 Sep 8.

7.

Mechanism of new antipsychotic medications: occupancy is not just antagonism.

Grunder G, Carlsson A, Wong DF.

Arch Gen Psychiatry. 2003 Oct;60(10):974-7. Review.

PMID:
14557141
8.

Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability.

DeLeon A, Patel NC, Crismon ML.

Clin Ther. 2004 May;26(5):649-66. Review.

PMID:
15220010
9.

Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic.

Keck PE Jr, McElroy SL.

Expert Opin Investig Drugs. 2003 Apr;12(4):655-62. Review.

PMID:
12665420
10.

[Pharmacology of antipsychotics at human dopamine D2 and D3 receptors].

Tadori Y, Kikuchi T.

Nihon Shinkei Seishin Yakurigaku Zasshi. 2012 Feb;32(1):9-18. Review. Japanese.

PMID:
22568121
11.

Aripiprazole: efficacy and tolerability profile of a novel-acting atypical antipsychotic.

Buckley PF.

Drugs Today (Barc). 2003 Feb;39(2):145-51. Review.

PMID:
12698209
12.

Aripiprazole acts as a selective dopamine D2 receptor partial agonist.

Wood M, Reavill C.

Expert Opin Investig Drugs. 2007 Jun;16(6):771-5. Review.

PMID:
17501690
13.

Aripiprazole in the treatment of depressive and anxiety disorders: a review of current evidence.

Pae CU, Serretti A, Patkar AA, Masand PS.

CNS Drugs. 2008;22(5):367-88. Review.

PMID:
18399707
14.

Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors.

Tadori Y, Forbes RA, McQuade RD, Kikuchi T.

Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40. doi: 10.1016/j.ejphar.2009.02.007. Epub 2009 Feb 13.

PMID:
19217900
15.

In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain.

Bortolozzi A, Díaz-Mataix L, Toth M, Celada P, Artigas F.

Psychopharmacology (Berl). 2007 Apr;191(3):745-58. Epub 2007 Jan 30.

PMID:
17265076
16.

Aripiprazole, an atypical antipsychotic, prevents the motor hyperactivity induced by psychotomimetics and psychostimulants in mice.

Leite JV, Guimarães FS, Moreira FA.

Eur J Pharmacol. 2008 Jan 14;578(2-3):222-7. Epub 2007 Oct 2.

PMID:
18021764
17.

Aripiprazole: what is the role of dopamine D(2) receptor partial agonism?

Kessler RM.

Am J Psychiatry. 2007 Sep;164(9):1310-2. No abstract available.

PMID:
17728411
18.

Switching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotic to aripiprazole.

Brown ES, Jeffress J, Liggin JD, Garza M, Beard L.

J Clin Psychiatry. 2005 Jun;66(6):756-60.

PMID:
15960570
19.

Aripiprazole in the treatment of patients with alcohol dependence: a double-blind, comparison trial vs. naltrexone.

Martinotti G, Di Nicola M, Di Giannantonio M, Janiri L.

J Psychopharmacol. 2009 Mar;23(2):123-9. doi: 10.1177/0269881108089596. Epub 2008 May 30.

PMID:
18515460
20.

The novel antipsychotic aripiprazole is a partial agonist at short and long isoforms of D2 receptors linked to the regulation of adenylyl cyclase activity and prolactin release.

Aihara K, Shimada J, Miwa T, Tottori K, Burris KD, Yocca FD, Horie M, Kikuchi T.

Brain Res. 2004 Apr 2;1003(1-2):9-17.

PMID:
15019558

Supplemental Content

Support Center